{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:11:20Z","timestamp":1787069480193,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,28]],"date-time":"2015-03-28T00:00:00Z","timestamp":1427500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13011-015-0009-2","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T16:42:09Z","timestamp":1427474529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio"],"prefix":"10.1186","volume":"10","author":[{"given":"Todd","family":"Molfenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Sherbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Zehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Quanbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,28]]},"reference":[{"issue":"11","key":"9_CR1","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson C, Moody DE, Woods JH, Kilbourn MR, Koeppe A, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"9_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130000637","volume":"154","author":"KB Stoller","year":"2001","unstructured":"Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine\/naloxone in opioid-dependent humans. Psychopharmacology. 2001;154(3):230\u201342.","journal-title":"Psychopharmacology"},{"issue":"6","key":"9_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1360-0443.2005.01106.x","volume":"100","author":"M Berglund","year":"2005","unstructured":"Berglund M. A better widget? Three lessons for improving addiction treatment from a meta\u2010analytical study. Addiction. 2005;100(6):742\u201350.","journal-title":"Addiction"},{"key":"9_CR4","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"2","key":"9_CR5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S0376-8716(03)00059-0","volume":"70","author":"W Ling","year":"2003","unstructured":"Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70(2):S49\u201357.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"9_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/ADM.0b013e3180473c11","volume":"1","author":"DA Fiellin","year":"2007","unstructured":"Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1(2):62\u20137.","journal-title":"J Addict Med"},{"key":"9_CR7","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. 2013: Rockville, MD."},{"issue":"1","key":"9_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1176\/appi.ps.201100034","volume":"63","author":"HK Knudsen","year":"2012","unstructured":"Knudsen HK, Abraham AJ. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatr Serv. 2012;63(1):19\u201325.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"9_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1747-597X-3-17","volume":"3","author":"LJ Ducharme","year":"2008","unstructured":"Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3(1):17.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"9_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5963\/PHF0201002","volume":"2","author":"T Molfenter","year":"2013","unstructured":"Molfenter T, McCarty D, Capoccia V, Gustafson D. Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics. Public Health Front. 2013;2(1):11\u201320.","journal-title":"Public Health Front"},{"issue":"1","key":"9_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/1475-6773.12093","volume":"49","author":"CJ Heinrich","year":"2014","unstructured":"Heinrich CJ, Cummings GR. Adoption and Diffusion of Evidence\u2010Based Addiction Medications in Substance Abuse Treatment. Health Serv Res. 2014;49(1):127\u201352.","journal-title":"Health Serv Res"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1077558713503188","volume":"71","author":"CM Andrews","year":"2014","unstructured":"Andrews CM, D\u2019Aunno TA, Pollack HA, Friedmann PD. Adoption of Evidence-Based Clinical Innovations: The Case of Buprenorphine Use by Opioid Treatment Programs. Med Care Res Rev. 2014;71:46\u201360.","journal-title":"Med Care Res Rev"},{"issue":"4","key":"9_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2006.05.021","volume":"32","author":"LJ Ducharme","year":"2007","unstructured":"Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. J Subst Abus Treat. 2007;32(4):321\u20139.","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"9_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jsat.2006.03.013","volume":"30","author":"HK Knudsen","year":"2006","unstructured":"Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abus Treat. 2006;30(4):363\u201373.","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"9_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","volume":"34","author":"HK Knudsen","year":"2011","unstructured":"Knudsen HK, Abraham AJ, Oser CB. Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34(4):375\u201381.","journal-title":"Eval Program Plann"},{"issue":"3","key":"9_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jsat.2005.02.003","volume":"28","author":"BE Fuller","year":"2005","unstructured":"Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H. Adoption of naltrexone to treat alcohol dependence. J Subst Abus Treat. 2005;28(3):273\u201380.","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"9_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.drugalcdep.2005.12.005","volume":"83","author":"AL Koch","year":"2006","unstructured":"Koch AL, Arfken CL, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006;83(3):274\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"9_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsat.2007.02.004","volume":"34","author":"CM Horgan","year":"2008","unstructured":"Horgan CM, Reif S, Hodgin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abus Treat. 2008;34(2):147\u201356.","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"9_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1377\/hlthaff.24.4.1005","volume":"24","author":"SA Schroeder","year":"2005","unstructured":"Schroeder SA. An agenda to combat substance abuse. Health Aff. 2005;24(4):1005\u201313.","journal-title":"Health Aff"},{"key":"9_CR20","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Uniform Reporting System (URS) Output Tables. 2013 [cited 2014 September, 24]; Available from: http:\/\/www.samhsa.gov\/dataoutcomes\/urs\/ ."},{"key":"9_CR21","volume-title":"DATA2010: The Healthy People 2010 Database","author":"Centers for Disease Control (CDC)","year":"2011","unstructured":"Centers for Disease Control (CDC). DATA2010: The Healthy People 2010 Database. Atlanta, GA: National Center for Health Statistics; 2011."},{"key":"9_CR22","volume-title":"2011 Ohio Drug Overdose Data: General Findings","author":"Ohio Department of Health, O.o.V.S","year":"2011","unstructured":"Ohio Department of Health, O.o.V.S. 2011 Ohio Drug Overdose Data: General Findings. 2011."},{"issue":"1","key":"9_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/1941-2851.1036","volume":"5","author":"RT Sherba","year":"2012","unstructured":"Sherba RT, Massatti RR, Potts L, Adhikari SB, Martt N, Starr S, et al. A Review of Ohio\u2019s Treatment Capacity in Addressing the State\u2019s Opiate Epidemic. J Drug Policy Anal. 2012;5(1):1\u201311.","journal-title":"J Drug Policy Anal"},{"issue":"1 Suppl B","key":"9_CR24","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.18553\/jmcp.2010.16.S1-B.14","volume":"16","author":"L Nicholls","year":"2010","unstructured":"Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14\u201321.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"9_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1475-6773.2007.00812.x","volume":"43","author":"CJ Heinrich","year":"2008","unstructured":"Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43(3):951\u201370.","journal-title":"Health Serv Res"},{"issue":"1","key":"9_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-8-50","volume":"8","author":"T Molfenter","year":"2013","unstructured":"Molfenter T, Kim J, Quanbeck A, Patel-Porter T, Starr S, McCarty D. Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Implement Sci. 2013;8(1):50.","journal-title":"Implement Sci"},{"issue":"9","key":"9_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"key":"9_CR28","unstructured":"ATLAS.ti, Version 6.1.16. 2011, Scientific Software Development."},{"issue":"2","key":"9_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"key":"9_CR30","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) (2000) Drug Addiction Treatment Act of 2000. Title XXXV, Section 3502 of the Children\u2019s Health Act of 2000. [cited 2014 November, 14]. Available at: http:\/\/buprenorphine.samhsa.gov\/data.html"},{"key":"9_CR31","volume-title":"Increasing heroin overdoses in Ohio: understanding the issue","author":"R Massatti","year":"2014","unstructured":"Massatti R, Beeghly C, Hall O, Kariisa M, Potts L. Increasing heroin overdoses in Ohio: understanding the issue. Columbus, OH: Ohio Department of Mental Health and Addiction Services; 2014."},{"issue":"2","key":"9_CR32","first-page":"83","volume":"12","author":"CB Forrest","year":"2006","unstructured":"Forrest CB, Villagra VV, Pope JE. Managing the metric vs managing the patient: the physician\u2019s view of pay for performance. Am J Manag Care. 2006;12(2):83\u20135.","journal-title":"Am J Manag Care"},{"issue":"24","key":"9_CR33","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMsa066253","volume":"356","author":"T Higashi","year":"2007","unstructured":"Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, et al. Relationship between number of medical conditions and quality of care. N Engl J Med. 2007;356(24):2496\u2013504.","journal-title":"N Engl J Med"},{"issue":"2","key":"9_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","volume":"29","author":"HK Knudsen","year":"2005","unstructured":"Knudsen HK, DuCharme LJ, Roman PM, Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abus Treat. 2005;29(2):95\u2013106.","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"9_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","volume":"30","author":"JC Veilleux","year":"2010","unstructured":"Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155\u201366.","journal-title":"Clin Psychol Rev"},{"issue":"10","key":"9_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang N, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949\u201358.","journal-title":"N Engl J Med"},{"issue":"9","key":"9_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s11606-007-0264-7","volume":"22","author":"CO Cunningham","year":"2007","unstructured":"Cunningham CO, Kunis HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325\u20139.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"9_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla HA, Baldwin L, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128\u201333.","journal-title":"Ann Fam Med"},{"issue":"9","key":"9_CR39","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","volume":"23","author":"AY Walley","year":"2008","unstructured":"Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393\u20138.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"9_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","volume":"5","author":"HK Knudsen","year":"2011","unstructured":"Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21.","journal-title":"J Addict Med"},{"issue":"2","key":"9_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/01.PHH.0000311888.06252.bb","volume":"14","author":"BA Rabin","year":"2008","unstructured":"Rabin BA, Brownson R, Haire-Joshua D, Kreuter MW, Weaver NL. A glossary for dissemination and implementation research in health. J Public Health Manag Pract. 2008;14(2):117\u201323.","journal-title":"J Public Health Manag Pract"},{"issue":"2","key":"9_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jsat.2006.09.002","volume":"32","author":"T Rieckmann","year":"2007","unstructured":"Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abus Treat. 2007;32(2):207\u201315.","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"9_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","volume":"39","author":"CL Arfken","year":"2010","unstructured":"Arfken CL, Johanson C, Menza S, Schuster R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abus Treat. 2010;39(2):96\u2013104.","journal-title":"J Subst Abus Treat"},{"issue":"16","key":"9_CR44","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2013.280377","volume":"310","author":"E Wood","year":"2013","unstructured":"Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. Jama. 2013;310(16):1673\u20134.","journal-title":"Jama"},{"issue":"2","key":"9_CR45","first-page":"201","volume":"114","author":"J Kennedy","year":"2011","unstructured":"Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114(2):201\u20136.","journal-title":"Drug Alcohol Depend"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-015-0009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13011-015-0009-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-015-0009-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-015-0009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T02:19:04Z","timestamp":1598840344000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-015-0009-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,28]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1186\/s13011-015-0009-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,28]]},"assertion":[{"value":"14 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"13"}}